Literature DB >> 2267280

Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes.

C Marguerie1, C C Bunn, H L Beynon, R M Bernstein, J M Hughes, A K So, M J Walport.   

Abstract

The clinical and laboratory features of 29 patients who had one of three anti-aminoacyl-tRNA synthetase autoantibodies, anti-Jo1 (histidyl-tRNA synthetase), anti-PL12 (alanyl-tRNA synthetase) or anti-PL7 (threonyl-tRNA synthetase) were analysed and compared with the findings of other published reports. These autoantibodies were found to be associated with a syndrome delineated by inflammatory myositis (24 patients) and pulmonary fibrosis (23 of 29), but also including inflammatory arthritis (26/29), keratoconjunctivitis sicca (17/29), sclerodactyly (21/29), Raynaud's phenomenon (27/29), hepatitis (8/29) and subcutaneous calcinosis (7/29). The most important clinical determinant of outcome in this group of patients was the severity of the interstitial pulmonary disease. No patient fulfilled the classification criteria for systemic lupus erythematosus, although 10 had autoantibodies to extractable nuclear antigens including Ro, La, RNP, and Sm, and two patients had anti-dsDNA antibodies. Although it seems unlikely that anti-aminoacyl-tRNA synthetase antibodies are directly responsible for causing disease, they may provide an important clue to the aetiology of this unusual syndrome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2267280     DOI: 10.1093/qjmed/77.1.1019

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  63 in total

Review 1.  Systemic sclerosis: an autoantibody mosaic.

Authors:  C C Bunn; C M Black
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 2.  Autoantibodies and overlap syndromes in autoimmune rheumatic disease.

Authors:  E C Jury; D D'Cruz; W J Morrow
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

3.  Is polymyositis or dermatomyositis in patients with rheumatoid arthritis induced or unveiled by anti-tumor necrosis factor treatment?

Authors:  Takao Nagashima; Seiji Minota
Journal:  Clin Rheumatol       Date:  2010-04-20       Impact factor: 2.980

4.  Antisynthetase syndrome associated with long-standing rheumatoid arthritis.

Authors:  Takao Nagashima; Masahiro Iwamoto; Seiji Minota
Journal:  Rheumatol Int       Date:  2010-03-30       Impact factor: 2.631

5.  A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy.

Authors:  Lisa Christopher-Stine; Livia A Casciola-Rosen; Grace Hong; Tae Chung; Andrea M Corse; Andrew L Mammen
Journal:  Arthritis Rheum       Date:  2010-09

6.  Rituximab in the treatment of antisynthetase syndrome.

Authors:  L Brulhart; J-M Waldburger; C Gabay
Journal:  Ann Rheum Dis       Date:  2006-07       Impact factor: 19.103

7.  Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease.

Authors:  Thomas J Richards; Aaron Eggebeen; Kevin Gibson; Samuel Yousem; Carl Fuhrman; Bernadette R Gochuico; Noreen Fertig; Chester V Oddis; Naftali Kaminski; Ivan O Rosas; Dana P Ascherman
Journal:  Arthritis Rheum       Date:  2009-07

8.  Interstitial lung disease in a child with antisynthetase syndrome.

Authors:  Don Hayes; Peter B Baker; Heidi M Mansour; Mark E Peeples; Kathleen K Nicol
Journal:  Lung       Date:  2013-05-08       Impact factor: 2.584

Review 9.  Myositis-specific autoantibodies: detection and clinical associations.

Authors:  Sander H J van Dooren; Walther J van Venrooij; Ger J M Pruijn
Journal:  Auto Immun Highlights       Date:  2011-03-23

10.  The long-term outcome of anti-Jo-1-positive inflammatory myopathies.

Authors:  Michael Späth; Mira Schröder; Beate Schlotter-Weigel; Maggie C Walter; Hubert Hautmann; Gerda Leinsinger; Dieter Pongratz; Wolfgang Müller-Felber
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.